Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Avacta selects Trinean’s DropSense96® for purified protein QC

Published: Monday, October 01, 2012
Last Updated: Monday, October 01, 2012
Bookmark and Share
Trinean announced that its DropSense96® droplet reader has been chosen by Avacta for High Throughput analysis of their purified Affimer proteins.

Avacta has established facilities capable of expressing and purifying 15,000 of their proprietary Affimer proteins every 6 weeks. These affinity reagents, which can be thought of as artificial antibodies, will be incorporated into very high complexity protein microarrays designed to revolutionize the discovery and validation of disease biomarkers. “The high complexity of the protein arrays means that the Affimers have to be produced to very high standards of purity and yield." said Paul Ko Ferrigno, Head of Discovery Technology at Avacta, "Our challenge is that quality control becomes a rate-limiting step when working at this high throughput .We currently have plates of purified Affimers stacked waiting for analysis by traditional methods. Once the Trinean DropSense96® is introduced into the workflow, quality control will become as automated as the purification protocols, allowing the development team to go from bacterial colony to purified protein of known concentration within 2 days, processing one thousand proteins at a time."

Philippe Stas, CEO of Trinean, added: "The decision by Avacta to use our DropSense96® droplet reader further validates our instruments to deliver high quality UV/Vis spectral absorbance data. The DropSense96® was designed to meet the requirements of protein purification labs by combining speed and minimal sample usage. Our unmatched large measurement range allows quantification of undiluted protein samples in real-time thereby significantly shortening the purification process.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Fructose Alters Hundreds of Brain Genes
UCLA scientists report that diet rich in omega-3 fatty acids can reverse the damage.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
New Genetic Risk Factors for Myopia Discovered
Genes and environment determine short-sightedness.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!